Connect with us

International

Novavax grabs another CFO while Pat Cotroneo retires from FibroGen; Eli Lilly reassembles key staff after biomedicines unit split

Jim Kelly
→ The perennial Charlie Brown of vaccine development, Novavax is grappling with Lucy’s knack for pulling the football away once again, this time with its Covid-19 vaccine as the FDA pushed back another bid for an EUA earlier this month….

Published

on

Jim Kelly

→ The perennial Charlie Brown of vaccine development, Novavax is grappling with Lucy’s knack for pulling the football away once again, this time with its Covid-19 vaccine as the FDA pushed back another bid for an EUA earlier this month. In the meantime, Novavax has found Jim Kelly to replace Greg Covino as CFO, leaving John Trizzino one less C-suite title to juggle. Kelly, the ex-CFO at Vanda Pharmaceuticals, was just in this space in October 2020 when he succeeded Greg Patrick as CFO of Supernus, and now he makes a quick change to a biotech that can’t seem to avoid taking on Sisyphean qualities no matter what it does.

Furthermore, Novavax has hired Nasir Egal away from Sanofi to be SVP of quality assurance. Egal rounded out nearly 10 years at Sanofi by leading global quality external affairs, and before that, he was responsible for quality and compliance in several regions for Novartis.

Pat Cotroneo

→ Finally catching a break with Europe’s approval of roxadustat after the FDA rejected it last week, FibroGen is changing CFOs, with Pat Cotroneo retiring on Labor Day to pave the way for Juan Graham on Sept. 7. Thus ends a 20-year association with J&J for Graham, the last two of those years as global CFO / VP, finance supply chain. Cotroneo had served as CFO since 2007 and will be CEO Enrique Conterno’s executive advisor until March 31, 2022. A month ago, CSO Percy Carter came on board the same week that an FDA adcomm voted against the anemia drug by wide margins.

Anne White

→ Using the Aduhelm affair to make the case for its own potential Alzheimer’s competitor donanemab, Eli Lilly is caught up in the fervor and has split Lilly Biomedicines into Lilly Neuroscience and Lilly Immunology. Anne White, president of Lilly Oncology, will now be president of Lilly Neuroscience, while Loxo Oncology at Lilly CEO Jake van Naarden will replace her and be responsible for bringing Loxo and Lilly Oncology’s brands together. Patrik Jönsson, a Lilly staffer since 1990, has been appointed president of Lilly Immunology and will also continue in his duties as SVP and president, Lilly USA and chief customer officer.

Additionally, Lilly International president Alfonso “Chito” Zulueta is retiring at the end of the year, with Lilly Biomedicines president Ilya Yuffa waiting to succeed him. Zulueta has been with the pharma giant since 1988, while Yuffa has devoted nearly a quarter century to Lilly. Our Kyle Blankenship has more on this cascade of changes.

Michael Parini

Freeline Therapeutics is placing enough confidence in Michael Parini only five months into his tenure as president and COO to promote him to CEO. Theresa Heggie leaves Freeline after an 18-month run that was marked by the London biotech’s IPO in August 2020 and a two-year delay on a pivotal trial for hemophilia B candidate FLT180a six months later because of CMC issues. Before Parini climbed aboard on March 15, Parini was EVP and chief administrative, legal and business development officer at Vertex.

Wolfgang Brysch

→ There’s a passing of the torch forthcoming at Swiss-based MetrioPharm — focused on chronic inflammatory diseases — as Thomas Christély takes over the CEO job from Wolfgang Brysch starting Oct. 1. Brysch, who co-founded MetrioPharm and has been chief executive since 2016, will settle into the dual roles of CSO and CMO. Christély was managing director and CFO of German HDV and HBV player MYR GmbH, which announced its sale to Gilead in December for $1.7 billion before Gilead’s head of virology Diana Brainard jumped to AlloVir.

→ RNA processing biotech Remix Therapeutics brought out the VIPs in its Series A round as ARCH, Foresite, The Column Group and Atlas all participated. President and CSO Peter Smith, an entrepreneur in residence at Atlas, has been bumped up to president and CEO at Remix eight months after its launch. Formerly in the oncology group at Millennium/Takeda, Smith was CSO at H3 Biomedicine before co-founding Remix with Atlas partner Kevin Bitterman.

→ Unlike FibroGen, Myovant and Pfizer earned the FDA’s approval with Myfembree for heavy menstrual bleeding associated with uterine fibroids in May, and on Sept. 7, Myovant welcomes Uneek Mehra as chief financial and business officer. Mehra, the CFO at PACT Pharma since October 2019, spent 13 years with Novartis in a number of capacities, from CFO of the US integrated care and critical care business units to global head of portfolio management, licensing and M&A for the oncology business. The Myfembree approval was an early win for Myovant CEO David Marek, who replaced Lynn Seely at the start of 2021.

Richard Buckley

Richard Buckley has parted ways with AstraZeneca to become chief corporate affairs officer at EQRx, one of many companies getting in on the SPAC craze by reverse merging with CM Life Sciences III in a deal worth $1.8 billion. To close out his 17 years at AstraZeneca, Buckley was Pascal Soriot’s VP, global corporate affairs, and has also served as Eli Lilly’s director of federal government affairs. Making cheaper drug prices their main objective, EQRx also made a CEO change when the SPAC deal was announced, as president and COO Melanie Nallicheri takes the top spot and Alexis Borisy shifts to the role of chairman on Sept. 1.

→ A sea of Yumanity: There’s been no shortage of hiring at Yumanity since it reverse merged last summer with Proteostasis Therapeutics, and CFO Michael Wyzga continues the trend. Wyzga, who was VP in the healthcare investment banking group during his eight years at Needham & Company, joins the list of such newcomers as head of R&D Ajay Verma and general counsel Devin Smith.

Linda Couto

→ North Carolina-based gene therapy group Atsena Therapeutics, which landed a $55 million Series A in December for clinical trials on ocular gene therapy, has brought on Linda Couto as its new CSO. Formerly the head of pharmacology, toxicology and ocular research at Spark Therapeutics, Couto joins Spark co-founder Jennifer Wellman at Atsena, who was named to the board of directors last month.

→ Portland-based startup Sparrow Pharmaceuticals, looking to cut down corticosteroid use with its lead candidate SPI-62, has tapped Frank Czerwiec as CMO and Jamie MacPherson as VP of regulatory affairs and quality. After 20 years with Otsuka, Czerwiec became CMO at Goldfinch Bio, a position he had held since December 2018. And MacPherson, the ex-director of regulatory affairs at Alexion, has been a regulatory exec with Akcea the last four years. OrbiMed-backed Sparrow took flight in May with $50 million in Series A financing.

Jubilant Therapeutics has recruited Leila Alland to its board of directors and Jeremy Barton as strategic advisor and interim CMO. Alland currently serves as CMO of PMV Pharmaceuticals and was previously the CMO of Affimed and Tarveda Therapeutics. As for Barton, he was previously CMO at Biogen, eFFECTOR Therapeutics and Mirati Therapeutics. In addition to those stints, Barton was head of early oncology development at Pfizer.

Jeff Gulcher

→ Concurrent with the Genuity Science buyout, HiberCell has poached several Genuity employees: Chief technology officer Tom Chittenden has been with the company since 2015 and was once chief data science officer; Genuity co-founder and CSO Jeff Gulcher becomes CSO of genomics; and chief informatics officer Hákon Guðbjartsson is Gulcher’s longtime colleague from their days at deCODE genetics and, before it became Genuity, NextCode Health. The $100 million all-stock deal comes after HiberCell’s $67.4 million Series B raise in May, all part of the biotech’s quest to see how stress biology and innate immunity contribute to cancer recurrence.

→ Immunotherapy startup Immunitas Therapeutics promoted Amanda Wagner this week to CBO, coupled with Immunitas’ recent success in obtaining $58 million in Series B financing for their lead program, a CD161-blocking antibody. Wagner was one of the earliest employees when she joined Immunitas in October 2019 as VP of strategy, one month before they officially launched. Before joining Immunitas, she was VP of corporate development at Q32 Bio after leaving Concert Pharmaceuticals, where she was VP of business development and product strategy for a decade.

Tushar Misra

→ Antibody-drug conjugate (ADC) biotech Mersana Therapeutics recently hired Tushar Misra as their CMO, succeeding the retiring Michael Kaufman, who will stay for a transition period that lasts until Sept. 10. A Takeda and Wave Life Sciences alum, Misra was the former head of manufacturing at Flagship-backed Laronde, a biotech startup led by Diego Miralles that officially launched in May with a $50 million Series A.

→ Going public in February with the help of SPAC-tician Rajiv Shukla in a $255 million deal, Laura Niklason-led Humacyte has locked in B.J. Scheessele as chief commercial officer. Scheessele, a former marketing director at LifeCell who stayed on at Allergan when Brent Saunders purchased the company in 2017, completes a three-year stay as Quest Medical Imaging’s EVP of global marketing.

Caryn Parlavecchio

→ Longtime Novartis vet Caryn Parlavecchio has signed on as chief human resources officer at Cambridge, MA-based Scholar Rock, which just replaced CEO Tony Kingsley a couple weeks ago with founder Nagesh Mahanthappa. Parlavecchio rose to VP and global HR head, oncology and pharma development during her 19 years at Novartis, and for the last year she’s been chief human resources officer at Holy Name Medical Center in Teaneck, NJ.

→ China-based bioconjugate developer GeneQuantum Healthcare has selected Kaida Wu as CMO. His experience reads like a veritable who’s-who of pharma: more than five years as a scientist of discovery medicine at AstraZeneca; three years as an oncology research investigator at Sanofi; another three years at Janssen; and finally, the last four years at Celgene/Bristol Myers Squibb, where he was recently involved in hematology/oncology and cell therapy (HOCT) at the Mechanisms of Cancer Resistance Thematic Research Center.

Cynthia Hu

→ Hearing loss biotech Decibel Therapeutics — which followed its Series D financing with a nine-figure IPO in February — has named Cynthia Hu chief legal officer and corporate secretary. Hu joined CASI Pharmaceuticals back in 2006 when it was known as EntreMed and was COO as well as VP, general counsel and secretary. In June, ex-Otsuka CEO William Carson became chairman of Decibel’s board.

→ This isn’t Evan Ballantyne’s first rodeo in the CFO seat as he hops aboard to take on the title at OncXerna Therapeutics. Ballantyne has served as the CFO of several companies, including Orchestra Biomed, Cerecin, Clinical Data, Synthetic Biologics, Avedro and ZymeQuest.

Sarah Glass

→ Founded and chaired by CEO Stanley Crooke, the non-profit n-Lorem Foundation has brought in its first-ever chief development officer with the appointment of Sarah Glass. Glass joins the company from Parexel, where she served as global head of rare diseases.

→ Amsterdam-based Lumicks has enlisted Paul Wheeler to be the company’s first CCO. Wheeler brings with him experience from his time at Luminex, Merck, PRW Bioscience, Singulex, Gyros, Oxford Immunotec and Guava Technologies.

Vanessa Ribreau

→ AI company BenchSci has welcomed Vanessa Ribreau as chief people officer. Ribreau was formerly the global VP of people, places, and technologies at AlayaCare. Additionally, BenchSci has pulled out a seat for Bonita Stewart on its board of directors. Stewart is a board partner at Google‘s venture fund Gradient Ventures. Prior to that role, Stewart spent 15 years at Google, most recently serving as their VP, global partnerships.

Recursion made everyone take notice with a gargantuan $436 million IPO in April, and the Salt Lake City-based AI drug developer has now enlisted Jordan Christensen as VP of engineering. Since 2017, Christensen has been VP of engineering at ecobee, which specializes in smart thermostats and other home automation technology.

→ All too accustomed to FDA roadblocks with its Duchenne muscular dystrophy gene therapy, Solid Bio has pegged Michael Inbar as VP of finance. Inbar, a former associate director of SEC reporting at Acceleron, has spent the last four years as VP, accounting and corporate controller at Syros Pharmaceuticals. Solid Bio has remained active on Peer Review this year since the promotion of COO Joel Schneider with the appointment of a chief regulatory officer and SVP of clinical development, among other new execs.

Angèle Maki

ReCode Therapeutics, the genetic medicines biotech backed by MPM and OrbiMed and led by former Amicus CSO David Lockhart, has brought on Angèle Maki as SVP of business development. Maki hails from Eli Lilly, where she was the Indianapolis pharma’s VP, venture science, corporate business development, and she also owns BD experience at Genentech, 23andMe and Merck.

Mary Coleman has been named VP, head of investor relations with Firdapse maker Catalyst Pharmaceuticals out of the Miami area. Coleman, who just held the same title at BioXcel, was VP, investor relations and communications for Jubilant Pharmaceuticals and covered similar bases during her time as senior director at Savient Pharmaceuticals from 2007-13.

Premier Research has brought some new execs into the fold with the appointments of Slawomir Wojtowicz-Praga (VP, global head of medical affairs), Ayesha Pandit (VP, medical oncology strategy), and Ashley Herrick (executive director, oncology strategy). Wojtowicz-Praga hops aboard with experience from stints at Genentech/Roche, Talon Therapeutics, Sankyo Pharma Development, Aventis and Theradex. Meanwhile, Pandit previously served in roles at AbbVie, J&J and the University of Texas MD Anderson Cancer Center. Last, but not least, Herrick joins from MD Anderson, where she served as senior clinical research program coordinator.

Mark Goldberg

Mark Goldberg is adding another stint to his résumé as non-executive director of cancer immunotherapy-focused Avacta. Goldberg is a medical oncologist and hematologist on the faculty of Brigham & Women’s Hospital and Harvard Medical School. Currently, Goldberg sits on the board of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences and Blueprint Medicines. In addition, Goldberg previously served on the board of Audentes.

→ Backed by the University of Pittsburgh Medical Center, T cell therapy player BlueSphere Bio has made ex-Amgen CFO Jonathan Peacock chairman of the board. Peacock is also a board member at Genmab and UCB, and he’s the lead director at Avantor.

Sara Bonstein

→ Equipped with a Series C round to propel its anti-CTLA-4 antibody and IL-2 agonist into the clinic, Xilio Therapeutics has elected Sara Bonstein to the board of directors. Currently the CFO at Insmed, Bonstein was also CFO and COO at OncoSec from 2018-20.

Neil Kumar’s BridgeBio has a trio of new board members, with former Schering-Plough CEO and current Warburg Pincus partner Fred Hassan leading the group. Andrea Ellis, the CFO of transportation outfit Lime, and former AIG chief investment officer Douglas Dachille also have seats on the board.

Tamara Seymour has hopped onto the board of directors of KemPharm. Seymour currently sits on the board of Artelo Biosciences and Kintara Therapeutics. Previously, Seymour has served as CFO of Signal Genetics (now Viridian Therapeutics) and HemaQuest Pharmaceuticals.

Scott Garland

→ PACT Pharma CEO Scott Garland has joined the board of directors at pediatric cancer biotech Day One Biopharmaceuticals, which raised $160 million in an upsized IPO this spring. The Merck, Amgen and Genentech vet also helmed Portola from 2018 until Alexion’s 2020 acquisition.

Rekha Hemrajani and Jason Coloma have been given seats on the board of directors at anti-aging upstart BioAge Labs — a board that also includes Vijay Pande. The ex-president and CEO of Aravive, Hemrajani is on the boards of MaxCyte and ALX Oncology, while Coloma has helmed Maze Therapeutics since 2019.

David Enloe

ViroCell Biologics has tapped Recro Pharma CEO David Enloe to be a part of its board of directors. Prior to his current role, Enloe was president and CEO of Ajinomoto Bio-Pharma Services and head of Lonza’s viral therapeutics business unit. In addition to Enloe’s appointment, the company has also brought on CAR-T expert Martin Pule to its scientific advisory board.

→ Gastrointestinal disease-focused AzurRx BioPharma has added BioDelivery Sciences EVP and CFO Terry Coelho to the board of directors. Coelho spent the back half of her seven years at Novartis as global head of oncology development finance.

→ San Diego-based Otonomy has reeled in Jill Broadfoot to its board of directors. Broadfoot currently serves as the CFO of aTyr Pharma and has previously been the CFO of Emerald Health Pharmaceuticals and Emerald Health Bioceuticals. Additionally, she has held roles at GW Pharmaceuticals and Vical.

Read More

Continue Reading

Government

Rand Paul Teases Senate GOP Leader Run – Musk Says “I Would Support”

Rand Paul Teases Senate GOP Leader Run – Musk Says "I Would Support"

Republican Kentucky Senator Rand Paul on Friday hinted that he may jump…

Published

on

Rand Paul Teases Senate GOP Leader Run - Musk Says "I Would Support"

Republican Kentucky Senator Rand Paul on Friday hinted that he may jump into the race to become the next Senate GOP leader, and Elon Musk was quick to support the idea. Republicans must find a successor for periodically malfunctioning Mitch McConnell, who recently announced he'll step down in November, though intending to keep his Senate seat until his term ends in January 2027, when he'd be within weeks of turning 86. 

So far, the announced field consists of two quintessential establishment types: John Cornyn of Texas and John Thune of South Dakota. While John Barrasso's name had been thrown around as one of "The Three Johns" considered top contenders, the Wyoming senator on Tuesday said he'll instead seek the number two slot as party whip. 

Paul used X to tease his potential bid for the position which -- if the GOP takes back the upper chamber in November -- could graduate from Minority Leader to Majority Leader. He started by telling his 5.1 million followers he'd had lots of people asking him about his interest in running...

...then followed up with a poll in which he predictably annihilated Cornyn and Thune, taking a 96% share as of Friday night, with the other two below 2% each. 

Elon Musk was quick to back the idea of Paul as GOP leader, while daring Cornyn and Thune to follow Paul's lead by throwing their names out for consideration by the Twitter-verse X-verse. 

Paul has been a stalwart opponent of security-state mass surveillance, foreign interventionism -- to include shoveling billions of dollars into the proxy war in Ukraine -- and out-of-control spending in general. He demonstrated the latter passion on the Senate floor this week as he ridiculed the latest kick-the-can spending package:   

In February, Paul used Senate rules to force his colleagues into a grueling Super Bowl weekend of votes, as he worked to derail a $95 billion foreign aid bill. "I think we should stay here as long as it takes,” said Paul. “If it takes a week or a month, I’ll force them to stay here to discuss why they think the border of Ukraine is more important than the US border.”

Don't expect a Majority Leader Paul to ditch the filibuster -- he's been a hardy user of the legislative delay tactic. In 2013, he spoke for 13 hours to fight the nomination of John Brennan as CIA director. In 2015, he orated for 10-and-a-half-hours to oppose extension of the Patriot Act

Rand Paul amid his 10 1/2 hour filibuster in 2015

Among the general public, Paul is probably best known as Capitol Hill's chief tormentor of Dr. Anthony Fauci, who was director of the National Institute of Allergy and Infectious Disease during the Covid-19 pandemic. Paul says the evidence indicates the virus emerged from China's Wuhan Institute of Virology. He's accused Fauci and other members of the US government public health apparatus of evading questions about their funding of the Chinese lab's "gain of function" research, which takes natural viruses and morphs them into something more dangerous. Paul has pointedly said that Fauci committed perjury in congressional hearings and that he belongs in jail "without question."   

Musk is neither the only nor the first noteworthy figure to back Paul for party leader. Just hours after McConnell announced his upcoming step-down from leadership, independent 2024 presidential candidate Robert F. Kennedy, Jr voiced his support: 

In a testament to the extent to which the establishment recoils at the libertarian-minded Paul, mainstream media outlets -- which have been quick to report on other developments in the majority leader race -- pretended not to notice that Paul had signaled his interest in the job. More than 24 hours after Paul's test-the-waters tweet-fest began, not a single major outlet had brought it to the attention of their audience. 

That may be his strongest endorsement yet. 

Tyler Durden Sun, 03/10/2024 - 20:25

Read More

Continue Reading

Spread & Containment

‘I couldn’t stand the pain’: the Turkish holiday resort that’s become an emergency dental centre for Britons who can’t get treated at home

The crisis in NHS dentistry is driving increasing numbers abroad for treatment. Here are some of their stories.

This clinic in the Turkish resort of Antalya is the official 'dental sponsor' of the Miss England competition. Diana Ibanez-Tirado, Author provided

It’s a hot summer day in the Turkish city of Antalya, a Mediterranean resort with golden beaches, deep blue sea and vibrant nightlife. The pool area of the all-inclusive resort is crammed with British people on sun loungers – but they aren’t here for a holiday. This hotel is linked to a dental clinic that organises treatment packages, and most of these guests are here to see a dentist.

From Norwich, two women talk about gums and injections. A man from Wales holds a tissue close to his mouth and spits blood – he has just had two molars extracted.

The dental clinic organises everything for these dental “tourists” throughout their treatment, which typically lasts from three to 15 days. The stories I hear of what has caused them to travel to Turkey are strikingly similar: all have struggled to secure dental treatment at home on the NHS.

“The hotel is nice and some days I go to the beach,” says Susan*, a hairdresser in her mid-30s from Norwich. “But really, we aren’t tourists like in a proper holiday. We come here because we have no choice. I couldn’t stand the pain.”

Seaside beach resort with mountains in the distance
The Turkish Mediterranean resort of Antalya. Akimov Konstantin/Shutterstock

This is Susan’s second visit to Antalya. She explains that her ordeal started two years earlier:

I went to an NHS dentist who told me I had gum disease … She did some cleaning to my teeth and gums but it got worse. When I ate, my teeth were moving … the gums were bleeding and it was very painful. I called to say I was in pain but the clinic was not accepting NHS patients any more.

The only option the dentist offered Susan was to register as a private patient:

I asked how much. They said £50 for x-rays and then if the gum disease got worse, £300 or so for extraction. Four of them were moving – imagine: £1,200 for losing your teeth! Without teeth I’d lose my clients, but I didn’t have the money. I’m a single mum. I called my mum and cried.

Susan’s mother told her about a friend of hers who had been to Turkey for treatment, then together they found a suitable clinic:

The prices are so much cheaper! Tooth extraction, x-rays, consultations – it all comes included. The flight and hotel for seven days cost the same as losing four teeth in Norwich … I had my lower teeth removed here six months ago, now I’ve got implants … £2,800 for everything – hotel, transfer, treatments. I only paid the flights separately.

In the UK, roughly half the adult population suffers from periodontitis – inflammation of the gums caused by plaque bacteria that can lead to irreversible loss of gums, teeth, and bone. Regular reviews by a dentist or hygienist are required to manage this condition. But nine out of ten dental practices cannot offer NHS appointments to new adult patients, while eight in ten are not accepting new child patients.

Some UK dentists argue that Britons who travel abroad for treatment do so mainly for cosmetic procedures. They warn that dental tourism is dangerous, and that if their treatment goes wrong, dentists in the UK will be unable to help because they don’t want to be responsible for further damage. Susan shrugs this off:

Dentists in England say: ‘If you go to Turkey, we won’t touch you [afterwards].’ But I don’t worry because there are no appointments at home anyway. They couldn’t help in the first place, and this is why we are in Turkey.

‘How can we pay all this money?’

As a social anthropologist, I travelled to Turkey a number of times in 2023 to investigate the crisis of NHS dentistry, and the journeys abroad that UK patients are increasingly making as a result. I have relatives in Istanbul and have been researching migration and trading patterns in Turkey’s largest city since 2016.

In August 2023, I visited the resort in Antalya, nearly 400 miles south of Istanbul. As well as Susan, I met a group from a village in Wales who said there was no provision of NHS dentistry back home. They had organised a two-week trip to Turkey: the 12-strong group included a middle-aged couple with two sons in their early 20s, and two couples who were pensioners. By going together, Anya tells me, they could support each other through their different treatments:

I’ve had many cavities since I was little … Before, you could see a dentist regularly – you didn’t even think about it. If you had pain or wanted a regular visit, you phoned and you went … That was in the 1990s, when I went to the dentist maybe every year.

Anya says that once she had children, her family and work commitments meant she had no time to go to the dentist. Then, years later, she started having serious toothache:

Every time I chewed something, it hurt. I ate soups and soft food, and I also lost weight … Even drinking was painful – tea: pain, cold water: pain. I was taking paracetamol all the time! I went to the dentist to fix all this, but there were no appointments.

Anya was told she would have to wait months, or find a dentist elsewhere:

A private clinic gave me a list of things I needed done. Oh my God, almost £6,000. My husband went too – same story. How can we pay all this money? So we decided to come to Turkey. Some people we know had been here, and others in the village wanted to come too. We’ve brought our sons too – they also need to be checked and fixed. Our whole family could be fixed for less than £6,000.

By the time they travelled, Anya’s dental problems had turned into a dental emergency. She says she could not live with the pain anymore, and was relying on paracetamol.

In 2023, about 6 million adults in the UK experienced protracted pain (lasting more than two weeks) caused by toothache. Unintentional paracetamol overdose due to dental pain is a significant cause of admissions to acute medical units. If left untreated, tooth infections can spread to other parts of the body and cause life-threatening complications – and on rare occasions, death.

In February 2024, police were called to manage hundreds of people queuing outside a newly opened dental clinic in Bristol, all hoping to be registered or seen by an NHS dentist. One in ten Britons have admitted to performing “DIY dentistry”, of which 20% did so because they could not find a timely appointment. This includes people pulling out their teeth with pliers and using superglue to repair their teeth.

In the 1990s, dentistry was almost entirely provided through NHS services, with only around 500 solely private dentists registered. Today, NHS dentist numbers in England are at their lowest level in a decade, with 23,577 dentists registered to perform NHS work in 2022-23, down 695 on the previous year. Furthermore, the precise division of NHS and private work that each dentist provides is not measured.

The COVID pandemic created longer waiting lists for NHS treatment in an already stretched public service. In Bridlington, Yorkshire, people are now reportedly having to wait eight-to-nine years to get an NHS dental appointment with the only remaining NHS dentist in the town.

In his book Patients of the State (2012), Argentine sociologist Javier Auyero describes the “indignities of waiting”. It is the poor who are mostly forced to wait, he writes. Queues for state benefits and public services constitute a tangible form of power over the marginalised. There is an ethnic dimension to this story, too. Data suggests that in the UK, patients less likely to be effective in booking an NHS dental appointment are non-white ethnic groups and Gypsy or Irish travellers, and that it is particularly challenging for refugees and asylum-seekers to access dental care.


This article is part of Conversation Insights
The Insights team generates long-form journalism derived from interdisciplinary research. The team is working with academics from different backgrounds who have been engaged in projects aimed at tackling societal and scientific challenges.


In 2022, I experienced my own dental emergency. An infected tooth was causing me debilitating pain, and needed root canal treatment. I was advised this would cost £71 on the NHS, plus £307 for a follow-up crown – but that I would have to wait months for an appointment. The pain became excruciating – I could not sleep, let alone wait for months. In the same clinic, privately, I was quoted £1,300 for the treatment (more than half my monthly income at the time), or £295 for a tooth extraction.

I did not want to lose my tooth because of lack of money. So I bought a flight to Istanbul immediately for the price of the extraction in the UK, and my tooth was treated with root canal therapy by a private dentist there for £80. Including the costs of travelling, the total was a third of what I was quoted to be treated privately in the UK. Two years on, my treated tooth hasn’t given me any more problems.

A better quality of life

Not everyone is in Antalya for emergency procedures. The pensioners from Wales had contacted numerous clinics they found on the internet, comparing prices, treatments and hotel packages at least a year in advance, in a carefully planned trip to get dental implants – artificial replacements for tooth roots that help support dentures, crowns and bridges.

Street view of a dental clinic in Antalya, Turkey
Dental clinic in Antalya, Turkey. Diana Ibanez-Tirado, CC BY-NC-ND

In Turkey, all the dentists I speak to (most of whom cater mainly for foreigners, including UK nationals) consider implants not a cosmetic or luxurious treatment, but a development in dentistry that gives patients who are able to have the procedure a much better quality of life. This procedure is not available on the NHS for most of the UK population, and the patients I meet in Turkey could not afford implants in private clinics back home.

Paul is in Antalya to replace his dentures, which have become uncomfortable and irritating to his gums, with implants. He says he couldn’t find an appointment to see an NHS dentist. His wife Sonia went through a similar procedure the year before and is very satisfied with the results, telling me: “Why have dentures that you need to put in a glass overnight, in the old style? If you can have implants, I say, you’re better off having them.”

Most of the dental tourists I meet in Antalya are white British: this city, known as the Turkish Riviera, has developed an entire economy catering to English-speaking tourists. In 2023, more than 1.3 million people visited the city from the UK, up almost 15% on the previous year.


Read more: NHS dentistry is in crisis – are overseas dentists the answer?


In contrast, the Britons I meet in Istanbul are predominantly from a non-white ethnic background. Omar, a pensioner of Pakistani origin in his early 70s, has come here after waiting “half a year” for an NHS appointment to fix the dental bridge that is causing him pain. Omar’s son had been previously for a hair transplant, and was offered a free dental checkup by the same clinic, so he suggested it to his father. Having worked as a driver for a manufacturing company for two decades in Birmingham, Omar says he feels disappointed to have contributed to the British economy for so long, only to be “let down” by the NHS:

At home, I must wait and wait and wait to get a bridge – and then I had many problems with it. I couldn’t eat because the bridge was uncomfortable and I was in pain, but there were no appointments on the NHS. I asked a private dentist and they recommended implants, but they are far too expensive [in the UK]. I started losing weight, which is not a bad thing at the beginning, but then I was worrying because I couldn’t chew and eat well and was losing more weight … Here in Istanbul, I got dental implants – US$500 each, problem solved! In England, each implant is maybe £2,000 or £3,000.

In the waiting area of another clinic in Istanbul, I meet Mariam, a British woman of Iraqi background in her late 40s, who is making her second visit to the dentist here. Initially, she needed root canal therapy after experiencing severe pain for weeks. Having been quoted £1,200 in a private clinic in outer London, Mariam decided to fly to Istanbul instead, where she was quoted £150 by a dentist she knew through her large family. Even considering the cost of the flight, Mariam says the decision was obvious:

Dentists in England are so expensive and NHS appointments so difficult to find. It’s awful there, isn’t it? Dentists there blamed me for my rotten teeth. They say it’s my fault: I don’t clean or I ate sugar, or this or that. I grew up in a village in Iraq and didn’t go to the dentist – we were very poor. Then we left because of war, so we didn’t go to a dentist … When I arrived in London more than 20 years ago, I didn’t speak English, so I still didn’t go to the dentist … I think when you move from one place to another, you don’t go to the dentist unless you are in real, real pain.

In Istanbul, Mariam has opted not only for the urgent root canal treatment but also a longer and more complex treatment suggested by her consultant, who she says is a renowned doctor from Syria. This will include several extractions and implants of back and front teeth, and when I ask what she thinks of achieving a “Hollywood smile”, Mariam says:

Who doesn’t want a nice smile? I didn’t come here to be a model. I came because I was in pain, but I know this doctor is the best for implants, and my front teeth were rotten anyway.

Dentists in the UK warn about the risks of “overtreatment” abroad, but Mariam appears confident that this is her opportunity to solve all her oral health problems. Two of her sisters have already been through a similar treatment, so they all trust this doctor.

Alt text
An Istanbul clinic founded by Afghan dentists has a message for its UK customers. Diana Ibanez-Tirado, CC BY-NC-ND

The UK’s ‘dental deserts’

To get a fuller understanding of the NHS dental crisis, I’ve also conducted 20 interviews in the UK with people who have travelled or were considering travelling abroad for dental treatment.

Joan, a 50-year-old woman from Exeter, tells me she considered going to Turkey and could have afforded it, but that her back and knee problems meant she could not brave the trip. She has lost all her lower front teeth due to gum disease and, when I meet her, has been waiting 13 months for an NHS dental appointment. Joan tells me she is living in “shame”, unable to smile.

In the UK, areas with extremely limited provision of NHS dental services – known as as “dental deserts” – include densely populated urban areas such as Portsmouth and Greater Manchester, as well as many rural and coastal areas.

In Felixstowe, the last dentist taking NHS patients went private in 2023, despite the efforts of the activist group Toothless in Suffolk to secure better access to NHS dentists in the area. It’s a similar story in Ripon, Yorkshire, and in Dumfries & Galloway, Scotland, where nearly 25,000 patients have been de-registered from NHS dentists since 2021.

Data shows that 2 million adults must travel at least 40 miles within the UK to access dental care. Branding travel for dental care as “tourism” carries the risk of disguising the elements of duress under which patients move to restore their oral health – nationally and internationally. It also hides the immobility of those who cannot undertake such journeys.

The 90-year-old woman in Dumfries & Galloway who now faces travelling for hours by bus to see an NHS dentist can hardly be considered “tourism” – nor the Ukrainian war refugees who travelled back from West Sussex and Norwich to Ukraine, rather than face the long wait to see an NHS dentist.

Many people I have spoken to cannot afford the cost of transport to attend dental appointments two hours away – or they have care responsibilities that make it impossible. Instead, they are forced to wait in pain, in the hope of one day securing an appointment closer to home.

Billboard advertising a dental clinic in Turkey
Dental clinics have mushroomed in recent years in Turkey, thanks to the influx of foreign patients seeking a wide range of treatments. Diana Ibanez-Tirado, CC BY-NC-ND

‘Your crisis is our business’

The indignities of waiting in the UK are having a big impact on the lives of some local and foreign dentists in Turkey. Some neighbourhoods are rapidly changing as dental and other health clinics, usually in luxurious multi-storey glass buildings, mushroom. In the office of one large Istanbul medical complex with sections for hair transplants and dentistry (plus one linked to a hospital for more extensive cosmetic surgery), its Turkish owner and main investor tells me:

Your crisis is our business, but this is a bazaar. There are good clinics and bad clinics, and unfortunately sometimes foreign patients do not know which one to choose. But for us, the business is very good.

This clinic only caters to foreign patients. The owner, an architect by profession who also developed medical clinics in Brazil, describes how COVID had a major impact on his business:

When in Europe you had COVID lockdowns, Turkey allowed foreigners to come. Many people came for ‘medical tourism’ – we had many patients for cosmetic surgery and hair transplants. And that was when the dental business started, because our patients couldn’t see a dentist in Germany or England. Then more and more patients started to come for dental treatments, especially from the UK and Ireland. For them, it’s very, very cheap here.

The reasons include the value of the Turkish lira relative to the British pound, the low cost of labour, the increasing competition among Turkish clinics, and the sheer motivation of dentists here. While most dentists catering to foreign patients are from Turkey, others have arrived seeking refuge from war and violence in Syria, Iraq, Afghanistan, Iran and beyond. They work diligently to rebuild their lives, careers and lost wealth.

Regardless of their origin, all dentists in Turkey must be registered and certified. Hamed, a Syrian dentist and co-owner of a new clinic in Istanbul catering to European and North American patients, tells me:

I know that you say ‘Syrian’ and people think ‘migrant’, ‘refugee’, and maybe think ‘how can this dentist be good?’ – but Syria, before the war, had very good doctors and dentists. Many of us came to Turkey and now I have a Turkish passport. I had to pass the exams to practise dentistry here – I study hard. The exams are in Turkish and they are difficult, so you cannot say that Syrian doctors are stupid.

Hamed talks excitedly about the latest technology that is coming to his profession: “There are always new materials and techniques, and we cannot stop learning.” He is about to travel to Paris to an international conference:

I can say my techniques are very advanced … I bet I put more implants and do more bone grafting and surgeries every week than any dentist you know in England. A good dentist is about practice and hand skills and experience. I work hard, very hard, because more and more patients are arriving to my clinic, because in England they don’t find dentists.

Dental equipment in a Turkish treatment room
Dentists in Turkey boast of using the latest technology. Diana Ibanez-Tirado, CC BY-NC-ND

While there is no official data about the number of people travelling from the UK to Turkey for dental treatment, investors and dentists I speak to consider that numbers are rocketing. From all over the world, Turkey received 1.2 million visitors for “medical tourism” in 2022, an increase of 308% on the previous year. Of these, about 250,000 patients went for dentistry. One of the most renowned dental clinics in Istanbul had only 15 British patients in 2019, but that number increased to 2,200 in 2023 and is expected to reach 5,500 in 2024.

Like all forms of medical care, dental treatments carry risks. Most clinics in Turkey offer a ten-year guarantee for treatments and a printed clinical history of procedures carried out, so patients can show this to their local dentists and continue their regular annual care in the UK. Dental treatments, checkups and maintaining a good oral health is a life-time process, not a one-off event.

Many UK patients, however, are caught between a rock and a hard place – criticised for going abroad, yet unable to get affordable dental care in the UK before and after their return. The British Dental Association has called for more action to inform these patients about the risks of getting treated overseas – and has warned UK dentists about the legal implications of treating these patients on their return. But this does not address the difficulties faced by British patients who are being forced to go abroad in search of affordable, often urgent dental care.

A global emergency

The World Health Organization states that the explosion of oral disease around the world is a result of the “negligent attitude” that governments, policymakers and insurance companies have towards including oral healthcare under the umbrella of universal healthcare. It as if the health of our teeth and mouth is optional; somehow less important than treatment to the rest of our body. Yet complications from untreated tooth decay can lead to hospitalisation.

The main causes of oral health diseases are untreated tooth decay, severe gum disease, toothlessness, and cancers of the lip and oral cavity. Cases grew during the pandemic, when little or no attention was paid to oral health. Meanwhile, the global cosmetic dentistry market is predicted to continue growing at an annual rate of 13% for the rest of this decade, confirming the strong relationship between socioeconomic status and access to oral healthcare.

In the UK since 2018, there have been more than 218,000 admissions to hospital for rotting teeth, of which more than 100,000 were children. Some 40% of children in the UK have not seen a dentist in the past 12 months. The role of dentists in prevention of tooth decay and its complications, and in the early detection of mouth cancer, is vital. While there is a 90% survival rate for mouth cancer if spotted early, the lack of access to dental appointments is causing cases to go undetected.

The reasons for the crisis in NHS dentistry are complex, but include: the real-term cuts in funding to NHS dentistry; the challenges of recruitment and retention of dentists in rural and coastal areas; pay inequalities facing dental nurses, most of them women, who are being badly hit by the cost of living crisis; and, in England, the 2006 Dental Contract that does not remunerate dentists in a way that encourages them to continue seeing NHS patients.

The UK is suffering a mass exodus of the public dentistry workforce, with workers leaving the profession entirely or shifting to the private sector, where payments and life-work balance are better, bureaucracy is reduced, and prospects for career development look much better. A survey of general dental practitioners found that around half have reduced their NHS work since the pandemic – with 43% saying they were likely to go fully private, and 42% considering a career change or taking early retirement.

Reversing the UK’s dental crisis requires more commitment to substantial reform and funding than the “recovery plan” announced by Victoria Atkins, the secretary of state for health and social care, on February 7.

The stories I have gathered show that people travelling abroad for dental treatment don’t see themselves as “tourists” or vanity-driven consumers of the “Hollywood smile”. Rather, they have been forced by the crisis in NHS dentistry to seek out a service 1,500 miles away in Turkey that should be a basic, affordable right for all, on their own doorstep.

*Names in this article have been changed to protect the anonymity of the interviewees.


For you: more from our Insights series:

To hear about new Insights articles, join the hundreds of thousands of people who value The Conversation’s evidence-based news. Subscribe to our newsletter.

Diana Ibanez Tirado receives funding from the School of Global Studies, University of Sussex.

Read More

Continue Reading

International

Beloved mall retailer files Chapter 7 bankruptcy, will liquidate

The struggling chain has given up the fight and will close hundreds of stores around the world.

Published

on

It has been a brutal period for several popular retailers. The fallout from the covid pandemic and a challenging economic environment have pushed numerous chains into bankruptcy with Tuesday Morning, Christmas Tree Shops, and Bed Bath & Beyond all moving from Chapter 11 to Chapter 7 bankruptcy liquidation.

In all three of those cases, the companies faced clear financial pressures that led to inventory problems and vendors demanding faster, or even upfront payment. That creates a sort of inevitability.

Related: Beloved retailer finds life after bankruptcy, new famous owner

When a retailer faces financial pressure it sets off a cycle where vendors become wary of selling them items. That leads to barren shelves and no ability for the chain to sell its way out of its financial problems. 

Once that happens bankruptcy generally becomes the only option. Sometimes that means a Chapter 11 filing which gives the company a chance to negotiate with its creditors. In some cases, deals can be worked out where vendors extend longer terms or even forgive some debts, and banks offer an extension of loan terms.

In other cases, new funding can be secured which assuages vendor concerns or the company might be taken over by its vendors. Sometimes, as was the case with David's Bridal, a new owner steps in, adds new money, and makes deals with creditors in order to give the company a new lease on life.

It's rare that a retailer moves directly into Chapter 7 bankruptcy and decides to liquidate without trying to find a new source of funding.

Mall traffic has varied depending upon the type of mall.

Image source: Getty Images

The Body Shop has bad news for customers  

The Body Shop has been in a very public fight for survival. Fears began when the company closed half of its locations in the United Kingdom. That was followed by a bankruptcy-style filing in Canada and an abrupt closure of its U.S. stores on March 4.

"The Canadian subsidiary of the global beauty and cosmetics brand announced it has started restructuring proceedings by filing a Notice of Intention (NOI) to Make a Proposal pursuant to the Bankruptcy and Insolvency Act (Canada). In the same release, the company said that, as of March 1, 2024, The Body Shop US Limited has ceased operations," Chain Store Age reported.

A message on the company's U.S. website shared a simple message that does not appear to be the entire story.

"We're currently undergoing planned maintenance, but don't worry we're due to be back online soon."

That same message is still on the company's website, but a new filing makes it clear that the site is not down for maintenance, it's down for good.

The Body Shop files for Chapter 7 bankruptcy

While the future appeared bleak for The Body Shop, fans of the brand held out hope that a savior would step in. That's not going to be the case. 

The Body Shop filed for Chapter 7 bankruptcy in the United States.

"The US arm of the ethical cosmetics group has ceased trading at its 50 outlets. On Saturday (March 9), it filed for Chapter 7 insolvency, under which assets are sold off to clear debts, putting about 400 jobs at risk including those in a distribution center that still holds millions of dollars worth of stock," The Guardian reported.

After its closure in the United States, the survival of the brand remains very much in doubt. About half of the chain's stores in the United Kingdom remain open along with its Australian stores. 

The future of those stores remains very much in doubt and the chain has shared that it needs new funding in order for them to continue operating.

The Body Shop did not respond to a request for comment from TheStreet.   

Read More

Continue Reading

Trending